Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer

Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer

Background: Anti-EGFR antibodies are a standard care for advanced KRAS-wild type colorectal cancers. Circulating tumor DNA (ctDNA) monitoring during therapy can detect emergence of KRAS mutant clones and early resistance to therapy.Case Presentation: We describe a 61-years-old man presenting a metas...

Full description

Bibliographic Details
Main Authors: Franciele H. Knebel, Fabiana Bettoni, Leonardo G. da Fonseca, Anamaria A. Camargo, Jorge Sabbaga, Denis L. Jardim
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Oncology
Subjects:
liquid biopsies
anti-EGFR therapy
colorectal cancer
drug resistance
monitoring
circulating tumor DNA
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00170/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00170/full

Similar Items